Composite Phenol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a compositionally controlled phenolic active intended for multi-dosage-form veterinary manufacture. Model identifiers are manufacturer-assigned rather than harmonised across producers; a representative parenteral grade may be designated CP-VET-IP with a particle-size ceiling of ≤50 µm, while oral premix and granule grades may be designated CP-VET-OP with a sieve fraction of ≥98% through a 250 µm screen determined by Ph. Eur. 2.9.12. The specification is not a single pharmacopoeial monograph; it is compiled from the phenol monograph, the Ph. Eur. 2034 general monograph for substances for veterinary use, and VICH impurity guidelines. Identity is confirmed by infrared absorption spectrophotometry according to Ph. Eur. 2.2.24, assay by liquid chromatography with UV detection according to Ph. Eur. 2.2.29, water content by Ph. Eur. 2.5.12, residual solvents by Ph. Eur. 2.4.24, and elemental impurities by Ph. Eur. 2.4.20 or VICH GL18. Incoming raw material testing should follow 21 CFR 211.84 and EU GMP Chapter 4. Published data for the exact composite composition is supplier-specific; therefore the release limits in the marketing authorisation dossier should be treated as the controlling parameter rather than generic literature values.

In oral powder and premix manufacture, the product is pre-blended with a carrier before addition to the main ribbon blender or ploughshare mixer to avoid localised high-concentration zones. A bin blender with fill volume 50–70% of rated capacity is used, and blend uniformity is assessed with stratified samples from 10–15 locations per validation batch. The uniformity criterion for oral powders is typically derived from Ph. Eur. 2.9.40; if the dosage is below 2 mg active per unit, the mass-based uniformity requirement is applied. Capsule filling on tamping-pin or dosator equipment requires bulk density and flow function data; when angle of repose exceeds 35°, a glidant such as colloidal silicon dioxide at 0.2–0.5% w/w is introduced. Published data for this API in high-speed dosator machines is limited; therefore fill weight and plug compression settings should be established during process qualification rather than transferred from single-active phenol grades.

What Distinguishes Composite Phenol Veterinary Grade API from Technical-Grade Phenolic Streams?

Technical-grade phenol intended for resin, fibre and adhesive feedstocks is routinely controlled for crystallisation point, colour and water, but it is not controlled for pyridine bases, cresol isomers, neutral oils and sulfur-containing organic species that are restricted in injectable and mucosal veterinary preparations. The veterinary API is a purified phenolic composition in which related substances are controlled under VICH GL10 and residual solvent limits are aligned with VICH GL11; the pharmacopoeial pure phenol assay is commonly specified at 99.0–100.5% on the anhydrous basis, and composite-grade suppliers typically maintain the assay within this band while tightening individual unspecified impurities to levels accepted for parenteral and ophthalmic formulations. Unlike chlorocresol or metacresol single-active products, the composite phenol veterinary grade API is supplied as a dry free-flowing solid with controlled particle-size distribution, reducing the melting-related agglomeration that can occur during warehouse storage in warm climates. The difference is operationally significant in high-shear dispensing rooms: a free-flowing powder can be transferred through split butterfly valves with less residue than a low-melting phenolic solid, and container discharge behaviour can be verified using USP <1174> powder flow test methods.

When wet granulation is used, the process is more sensitive to liquid addition rate than to dry blending time. In a high-shear granulator with impeller tip speed 5–15 m/s and chopper speed 1000–3000 rpm, the binder solution is added until the granule median diameter reaches 100–300 µm for tablet compression. A deviation above +2% w/w liquid-to-solid ratio can shift the granule size distribution and alter disintegration time tested according to Ph. Eur. 2.9.1. In twin-screw wet granulation, screw configurations with an L/D ratio of 20:1 to 40:1 and a sequence of conveying, kneading and size-control elements are used; the powder feed rate and temperature-controlled barrel sections are adjusted so that the mass temperature avoids melting-related agglomeration of the phenolic active.

Granulation, Compression and Coating Constraints for Tablet and Capsule Applications

Direct compression is feasible only when the particle-size distribution of the composite phenolic API overlaps sufficiently with the filler-binder system. Tablet press speed and pre-compression force are adjusted so that ejection force remains below the tooling manufacturer limit; tablet friability below 1.0% is typically required for coated tablets, and disintegration is controlled by Ph. Eur. 2.9.1. Tablet cores containing the composite phenolic API may require non-aqueous film coating if aqueous coating causes surface dissolution or phenolic migration; when aqueous coating is used, pan bed temperature and spray rate must be balanced to limit moisture uptake. Dissolution testing according to Ph. Eur. 2.9.3 or USP <711> should use a medium relevant to the target species and administration route.

For capsules, the filled mass is controlled by tamping-pin height or dosator piston setting rather than by simple gravity flow. Composite phenolic API batches with electrostatic charging can exhibit carryover and weight variation; the problem is monitored by in-process weight checks, and content uniformity is assessed according to Ph. Eur. 2.9.40 for low-dose forms.

For parenteral manufacture, the API is dissolved or suspended in a closed, light-protected vessel under nitrogen sparging in a Class C area with local Class A filling following EU GMP Annex 1. Sub-visible particulate matter is controlled by Ph. Eur. 2.9.19 or USP <788>; for solution formulations, filter compatibility tests should be performed with PVDF or PES membrane filters at the maximum batch filtration throughput. Endotoxin loading in the API should be specified according to Ph. Eur. 2.6.14; a supplier release limit of ≤0.25 EU/mg is common for parenteral-grade phenolic actives when the maximum veterinary dose supports that limit, but the finished-product limit must be derived from the labeled dose and route of administration. The solution pH should be maintained within the range validated for the finished product; because phenolic active may influence pH and solubility, buffer selection and tonicity adjustment are performed with reference to Ph. Eur. 5.1.3 preservative effectiveness or USP <51> when the formulation is multi-dose. Terminal sterilisation at 121°C for 15 min is used only if the thermal stability of the composite API in the finished vehicle has been demonstrated; otherwise aseptic filtration is used and the API must comply with the bioburden and sterility requirements of Ph. Eur. 2.6.1 and Ph. Eur. 2.6.12/2.6.13.

For oral solutions and drinking-water formulations, the solution-grade API is transferred into a batching vessel containing purified water. Oral solutions prepared for drinking-water administration should be protected from light because phenolic oxidation may produce coloured degradation products. Continuous in-line mixing is preferred over batchwise manual addition to reduce localised high-pH zones; solution homogeneity is verified by sampling at the beginning, middle and end of the recirculation period. Filtration through a 10–20 µm cartridge before transfer to the filling line removes undissolved carrier but is not a sterilising step; therefore the oral solution must still meet the microbial limits of Ph. Eur. 2.6.12/2.6.13 and should be evaluated for antimicrobial preservation if multi-dose containers are used.

When the Same Active Is Required Across Premix, Solution, and Injectable Platforms

In multi-product veterinary facilities, the same chemical entity may be used for oral premixes, drench solutions and injectable solutions, but the release specifications for each grade differ. Oral premix and granule grades are controlled for particle size, bulk density and blend homogeneity, but they may carry a higher bioburden than a parenteral grade because they are not expected to be sterile. Premix blending in a horizontal ribbon blender or a single-shaft ploughshare mixer is monitored with sample collection from 8–15 locations; homogeneity acceptance is often set at 90.0–110.0% of label claim with an RSD below 5.0% across top, middle and bottom sampling positions. Solution-grade material for oral drench or drinking-water use is dissolved in a stainless-steel vessel with a recirculation loop; dissolution is confirmed by in-line refractive index or UV absorbance against a validated calibration curve, and the final solution is filtered before transfer to the filling line.

When the same API is designated for injectable use, the manufacturing route is not interchangeable without revalidation: the parenteral grade is milled under inert conditions and controlled for sub-visible particulates, endotoxins and total microbial count. The composite phenol veterinary grade API differs from single-use oral-only phenolic grades by offering a tighter residual solvent profile and a documented elemental impurity risk assessment under VICH GL18. Equipment contact surfaces for injectable manufacture should be 316L stainless steel with surface roughness Ra ≤ 0.8 µm on product-contact areas, cleaned and sterilised according to validated procedures.

Compliance Matrix for Release Testing

The release testing programme should be structured as a matrix because the same active may be released for different dosage-form routes with different risk levels. The table below summarises method anchors rather than universal limits; the definitive limits belong in the supplier specification and the marketing authorisation dossier.

The operational boundary for handling is set by the product’s tendency to generate fine dust and its resistance to extreme pH. Composite phenol veterinary grade API should not be blended with strong oxidising agents, hypochlorite-based sanitising solutions, or alkaline carriers outside the pH range validated for the finished product; uncontrolled exothermic degradation may occur. In solid-dosage manufacturing, the API should be stored at controlled room temperature and protected from moisture; at relative humidity above 60%, pre-drying may be required before direct compression because water uptake can increase sticking and reduce flow. Photostability of dry powder and final solution should be assessed under VICH GL5 from early development; amber glass or opaque polymer packaging is typically selected if the final solution darkens at light doses above the qualified limit. Batch-to-batch variability in particle-size distribution and residual water content must be tracked with statistical process control, and any change in supplier or milling site requires revalidation because the composite nature of the API may not be fully captured by the pharmacopoeial phenol monograph.